If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() International Journal of Dental HygieneEarly View (Articles online in advance of print)Published Online: 2 Nov 2009 © 2009 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 413K) | Related Articles | Citation Tracking ORIGINAL ARTICLE The plaque inhibitory effect of a CPC mouthrinse in a 3-day plaque accumulation model – a cross-over study Copyright © 2009 John Wiley & Sons A/S KEYWORDS cetylpyridinium chloride • clinical trial • dental plaque • hexetidine • mouthrinse
To cite this article:
Int J Dent Hygiene DOI: 10.1111/j.1601-5037.2009.00421.x Versteeg PA, Rosema NAM, Hoenderdos NL, Slot DE, van der Weijden GA. The plaque inhibitory effect of a CPC mouthrinse in a 3-day plaque accumulation model – A cross-over study. ABSTRACTObjective: To test the plaque inhibitory effect of an experimental 0.07% cetylpyridinium chloride (CPC) mouthrinse in a 3-day plaque accumulation model in a cross-over design. Material and Methods: A total of 30 subjects (non-dental students), ≥18 years of age, were randomly assigned to use one of three different mouthrinses three times a day. After 3 days, the subjects returned for the clinical assessments and received a questionnaire to evaluate their attitude towards the product used by them. The cross-over procedure was repeated twice to have all subjects use all products. Results: A total of 29 subjects completed the protocol and this resulted in a statistically significant difference between the three groups (P < 0.001) with regard to plaque scores. Over three sessions, the mean plaque scores were 2.17 for the control product, 1.14 for the CPC group and 1.12 for the 0.1% Hexetidine product (positive control). Results of the questionnaire show that, compared with hexetidine, the taste of the CPC was appreciated better, and less oral sensations were observed following rinsing. Conclusion: The CPC mouthrinse proved to be effective in inhibiting 'de novo' plaque formation to an extent similar to that of a 0.1% hexetidine product. Compared with hexetidine, the taste of the CPC was appreciated better and less oral sensations were observed following rinsing. Dates: Accepted 10 September 2009 |